Skip to main content
. 2021 Apr 25;12(1):1360–1368. doi: 10.1080/21655979.2021.1917980

Figure 2.

Figure 2.

A HUVEC viability in the blank group, HSA, M-HSA and M-HSA+FPS-ZM1 (CCK-8) **P < 0.01; B-C HUVEC viability in the blank group, HSA, M-HSA and M-HSA+FPS-ZM1 (flow cytometry) ##P < 0.01, ***P < 0.001